RDIF told about results of Sputnik V vaccination in Bahrain

10 June


The use of the Russian vaccine Sputnik V against coronavirus during a population vaccination in Bahrain confirmed its effectiveness above 90% and safety, the Russian Direct Investment Fund (RDIF) announced.


"The RDIF announces data from the Ministry of Health of the Kingdom of Bahrain on the use of the Russian Sputnik V coronavirus vaccine, which demonstrates its high efficacy and safety in the population vaccination," the fund said.


"An efficacy study conducted in Bahrain in accordance with WHO recommendations with the participation of more than 5,000 people confirmed the effectiveness of the drug at 94.3% 14 days after receiving the second component. The data obtained between February and early May of this year were analyzed," the RDIF also noted.


At the same time, 98.6% of all coronavirus cases recorded two weeks after receiving the second component of Sputnik V were mild.


Vaccination data in Bahrain also confirmed the safety of Sputnik V: there were no serious adverse events associated with vaccination with the Russian drug, no vaccine-related deaths and no cases of cerebral venous thrombosis (CVT) after vaccination.


Sputnik V demonstrates an efficacy rate of 94.3% and a high safety record, which confirms the statistics obtained in several other countries. The Russian vaccine is an important part of Bahrain's diversified national portfolio. The use of Sputnik V makes a significant contribution to reducing the number of new cases of coronavirus, restoring economic activity and a return to normal life," commented Kirill Dmitriev, the head of the RDIF.


The Russian Sputnik V coronavirus vaccine has already been approved in 67 countries with a total population of more than 3.4 billion people. Sputnik V has the second-highest number of approvals by state regulators in the world. The effectiveness of the vaccine was 97.6% based on analysis of data from 3.8 million vaccinated Russians, higher than the data previously published by The Lancet medical journal (91.6%), the Russian Direct Investment Fund (RDIF) and Gamaleya Research Center previously reported.

 

 

GSV "Russia - Islamic World"

Photo: Creative Commons

Based on materials from RIA Novosti